Intensive care medicine

Recce Pharmaceuticals Announces RECCE® Trademark Registered in Vietnam, Strengthening Global IP Portfolio

Retrieved on: 
Thursday, September 7, 2023
Antibiotic, International Trademark Association, Intellectual property, ASX, Colistin, FSE, IP, Intensive care medicine, World Organization of the Scout Movement, Hospital, Carbapenem, RCE, Pharmaceutical industry

SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce it has been issued a trademark registration for RECCE® from the Intellectual Property Office of Vietnam, strengthening the Company’s global intellectual property (IP) portfolio.

Key Points: 
  • SYDNEY, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce it has been issued a trademark registration for RECCE® from the Intellectual Property Office of Vietnam, strengthening the Company’s global intellectual property (IP) portfolio.
  • The International Trademark Registration No.
  • 1289603 has been formally assigned to the International Bureau (World Intellectual Property Organization), classified under Class 5 for antibiotics, antibiotics for human use, and pharmaceutical preparations, namely mixed antibiotic preparations.
  • “We are thrilled to receive this newly awarded trademark in Vietnam, further strengthening Recce’s intellectual property portfolio in the Asia-Pacific region,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

CalmWave Appoints Howard Wilson, CFO of PagerDuty, to Board of Advisors

Retrieved on: 
Wednesday, September 13, 2023
Nursing, Health, Technology, Hospitals, Practice Management, Health Technology, Artificial Intelligence, Cloud, Operation, Enterprise, PagerDuty, Health care, Multimedia, Central Waqf Council, Wilson, Intensive care medicine, Data, CFO, ICU, AI, Fatigue, Software, Management

CalmWave , the company leveraging AI to gauge hospitals’ Operations Health to improve nurse retention and patient outcomes by reducing alarm fatigue in intensive care units, today announced the appointment of Howard Wilson, CFO of PagerDuty, to the company's Board of Advisors.

Key Points: 
  • CalmWave , the company leveraging AI to gauge hospitals’ Operations Health to improve nurse retention and patient outcomes by reducing alarm fatigue in intensive care units, today announced the appointment of Howard Wilson, CFO of PagerDuty, to the company's Board of Advisors.
  • Wilson's appointment to the advisory board marks its expansion beyond world-class subject matter expert clinicians to include renowned IT and Operations leaders.
  • View the full release here: https://www.businesswire.com/news/home/20230913976271/en/
    “Howard is a champion of innovation and understands the big picture from an IT Operations and CFO perspective.
  • As CFO at PagerDuty, he leads the company’s internal and strategic execution, driving the company’s scaling initiatives.

New Multicenter Study Reveals Neurological Pupil index™ (NPi) as Predictor of Outcome and Mortality in Brain Injury Patients

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Optical, Surgery, General Health, Health, Medical Devices, Hospitals, Health Technology, Cardiac arrest, Lancet Neurology, Brain, Stroke, ICH, Multimedia, TBI, Intensive care medicine, Hospital, HIV disease progression rates, MD, Patient, Risk, Traumatic brain injury, Neurological pupil index, Seizure, Pupilometer, Neurology, Intracerebral hemorrhage, Mortality, Trial of the century, The Lancet, NPI, Medical imaging, Nursing, Anesthesia

The primary aim of the study was to investigate the association between NPi and 6-month neurological outcomes and mortality.

Key Points: 
  • The primary aim of the study was to investigate the association between NPi and 6-month neurological outcomes and mortality.
  • Patients' NPi scores were measured using NeurOptics' NPi Pupillometer every four hours during the initial seven days of admission.
  • "Tracking a patient's NPi score dynamically predicts their neurological outcome and mortality over a 6-month period.
  • The study, titled "The Neurological Pupil Index for Outcome Prognostication in People with Acute Brain Injury (ORANGE): A Prospective, Observational, Multicenter Cohort Study," is accessible here .

EQS-News: International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Retrieved on: 
Wednesday, September 6, 2023
Royal Surrey County Hospital, Hospice and palliative medicine, University, Consultant, E pluribus unum, RRT, Critical Care (journal), Overalls, Renal replacement therapy, Biomarker, AKI, Intensive care medicine, Acute kidney injury, CRRT, Professor, University Hospital Heidelberg, Patient, School, RICH, Mortality, University of Surrey, Intensive care unit, Health, Southern Illinois University School of Medicine, Pharmaceutical industry, Medical imaging, Nursing

Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.

Key Points: 
  • Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.
  • RRT, a common practice in Intensive Care Units (ICUs), has long relied on clinical observations for stop decisions.
  • However, the lack of a dependable biomarker poses challenges in accurately assessing when to discontinue RRT.
  • Considering this, leading experts from the field have discussed in a recent advisory board the importance of identifying the right tools to improve the outcomes in AKI.

EoS Fitness Opens Doors to New Gym in Phoenix

Retrieved on: 
Thursday, August 31, 2023
Men, Sports, General Health, Other Retail, General Sports, Family, Consumer, Other Sports, Fitness & Nutrition, Retail, Women, Health, Intensive care medicine, Tank, EGYM, Grand Canyon University, Inflammation, Eos, Chemical oxygen demand, Growth, Relaxation, Perspiration, Interior design

EoS Fitness ( www.eosfitness.com ), a nationwide gym chain that got its start in Arizona and now counts more than 125+ locations open or on the way, is welcoming members to its newest location in Phoenix.

Key Points: 
  • EoS Fitness ( www.eosfitness.com ), a nationwide gym chain that got its start in Arizona and now counts more than 125+ locations open or on the way, is welcoming members to its newest location in Phoenix.
  • The brand-new gym features 40,000 square feet of high-end amenities, including top-of-the-line cardio equipment, smart technology strength training machines and innovative recovery options.
  • “Our commitment to growth in the Grand Canyons State runs deep,” said Richard Idgar, COO of EoS Fitness.
  • “EoS opened its first gym in Arizona in 2015 and now we have nearly 30 locations across the state.

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Retrieved on: 
Wednesday, August 30, 2023
Biologics license application, IMV, Therapy, C5a, Senior, The Lancet, SARS-CoV-2, Biotechnology, Extracorporeal membrane oxygenation, European Medicines Agency, COVID-19, Survival, ECMO, European Directive on Traditional Herbal Medicinal Products, EDT, Marketing, Intensive care medicine, EMA, Food and Drug Administration, Emergency Use Authorization, Patient, European, Webcast, Mortality, Septic, MAA, Regulatory affairs, FDA, BLA, Food, CHMP, Pharmaceutical industry, EU

This means that the application is now under regulatory review by the European Committee for Medicinal Products for Human Use (CHMP) under the centralized procedure, which applies to all 27 member states of the European Union (EU).

Key Points: 
  • This means that the application is now under regulatory review by the European Committee for Medicinal Products for Human Use (CHMP) under the centralized procedure, which applies to all 27 member states of the European Union (EU).
  • InflaRx submitted the MAA to EMA in July 2023 following interactions with the rapporteur and co-rapporteur teams of the CHMP.
  • The results showed that vilobelimab treatment improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set.
  • “We are pleased that EMA has accepted our MAA submission and that it is now under review.

Epineuron Announces Enrollment of its First Patient in REGAIN™

Retrieved on: 
Wednesday, August 30, 2023
Medical Devices, Health, Neurology, Clinical Trials, Research, Science, Intensive care medicine, Surgeon, University, Nerve, DRS, Sympathetic nervous system, Therapy, Injury, Patient, Neuroregeneration, FDA, Safety, Pharmaceutical industry, MD

Epineuron , a clinical-stage nerve care company, announced it has successfully enrolled the first patient in the company’s pivotal trial, REGAIN™ .

Key Points: 
  • Epineuron , a clinical-stage nerve care company, announced it has successfully enrolled the first patient in the company’s pivotal trial, REGAIN™ .
  • The study aims to enroll up to 110 patients across Canada and the United States of America, making it the largest medical device study for nerve regeneration.
  • Dr. Ming Chan, MD, commented, “The first patient enrollment is an exciting milestone for Epineuron and witnessing the translation of scientific advancement from bench to bedside is truly remarkable.
  • With innovation and collaboration their team strives to redefine the standard of care for peripheral nerve treatment and improve patient outcomes.

Magellan Healthcare Selected to Administer Behavioral Health Services for Children, Youth and their Families in Nevada

Retrieved on: 
Tuesday, August 29, 2023
Public Policy, Government, Mental Health, State, Local, Health, Other Health, Managed Care, General Health, Health care, Human, Magellan Health, Nevada Division of Child and Family Services, Intensive care medicine, Division, Risk, Nevada Department of Health and Human Services, Intensive word form, Ferdinand Magellan, Family, Nursing, Child

Magellan Health, Inc. , a leader in behavioral health and related services, announced today that its subsidiary, Magellan Healthcare, Inc. , has been awarded the care management entity contract by the Nevada Department of Health and Human Services – Division of Child and Family Services.

Key Points: 
  • Magellan Health, Inc. , a leader in behavioral health and related services, announced today that its subsidiary, Magellan Healthcare, Inc. , has been awarded the care management entity contract by the Nevada Department of Health and Human Services – Division of Child and Family Services.
  • Magellan will be responsible for providing a comprehensive and coordinated approach to care and support for children and youth, ages three to 20, with complex behavioral health needs who are at risk for placement outside of their homes or communities.
  • In collaboration with the Division of Child and Family Services, Magellan will work to build a sustainable program that keeps children in Nevada at home and thriving.
  • “Magellan Healthcare is deeply honored to have been selected as the care management entity for this statewide contract and looks forward to partnering with the state to serve the behavioral health needs of children and adolescents throughout Nevada,” said Caroline Carney, M.D., president of behavioral health and chief medical officer of Magellan Health.

Backsliding on COVID Data is a Global Health Threat, Says AHF

Retrieved on: 
Monday, August 28, 2023
COVID-19, Infectious Diseases, Advocacy Group Opinion, Public Policy, Government, Other Health, AIDS, General Health, Health, Other Policy Issues, AHF, Global Public Health (journal), United Nations, Health policy, HIV, Public, Negotiation, COVID-19 deaths, Intensive care medicine, Death, Pandemic, Patient, AIDS Healthcare Foundation, WHO, Intensive care unit, World Health Organization, Pharmaceutical industry

“Without timely and reliable data, we could be flying blind into a new, deadly strain of COVID-19, and we wouldn’t even know it.

Key Points: 
  • “Without timely and reliable data, we could be flying blind into a new, deadly strain of COVID-19, and we wouldn’t even know it.
  • Parties involved in negotiating the Global Public Health Agreement must exert maximum effort to ensure data sharing and transparency become a fundamental part of the new pandemic accord,” said AHF President Michael Weinstein.
  • The global response to HIV has long been hampered by poor data reporting.
  • To prevent and effectively fight pandemics and outbreaks, frontline responders must have reliable and timely data – it is of utmost importance to global public health security.”

Global Vital Signs Monitoring Devices Market Outlook & Forecast Report 2023: A $33.35+ Billion Industry by 2028 - Patient-Centric Digital Systems and Wearable Devices Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 24, 2023
Medical Devices, Health, Telehealth, Hospital, Disability, Internet of things, Ageing, Quality of life, Electronic health record, Intensive care medicine, Internet, Chronic condition, Vital signs, Developed country, Patient, Risk, Disease, Conditional sentence, Growth, Mortality, RPM, Health information management, Medical device, Health insurance

The "Vital Signs Monitoring Devices Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vital Signs Monitoring Devices Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • With the advances in technologies in the vital signs monitoring devices market, advanced vital sign devices become more common in various healthcare filed and across daily lives.
  • The increasing demand for remote patient monitoring is accelerating the growth of the vital signs monitoring devices market.
  • The global vital signs monitoring devices market by product is segmented into standalone and integrated vital sign monitoring devices.